Home > Publications Database > Glial Purinergic Signaling in Neurodegeneration. > print

001     157732
005     20240328115556.0
024 7 _ |a 10.3389/fneur.2021.654850
|2 doi
024 7 _ |a pmid:34054698
|2 pmid
024 7 _ |a pmc:PMC8160300
|2 pmc
024 7 _ |a altmetric:105841238
|2 altmetric
037 _ _ |a DZNE-2021-01189
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Pietrowski, Marie J
|0 P:(DE-2719)2812560
|b 0
|e First author
245 _ _ |a Glial Purinergic Signaling in Neurodegeneration.
260 _ _ |a Lausanne
|c 2021
|b Frontiers Research Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1711546509_24240
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Purinergic signaling regulates neuronal and glial cell functions in the healthy CNS. In neurodegenerative diseases, purinergic signaling becomes dysregulated and can affect disease-associated phenotypes of glial cells. In this review, we discuss how cell-specific expression patterns of purinergic signaling components change in neurodegeneration and how dysregulated glial purinergic signaling and crosstalk may contribute to disease pathophysiology, thus bearing promising potential for the development of new therapeutical options for neurodegenerative diseases.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a ATP
|2 Other
650 _ 7 |a Alzheimer
|2 Other
650 _ 7 |a adenosine
|2 Other
650 _ 7 |a astrocyte
|2 Other
650 _ 7 |a microglia
|2 Other
650 _ 7 |a neurodegeneration
|2 Other
650 _ 7 |a oligodendrocyte
|2 Other
650 _ 7 |a purine
|2 Other
700 1 _ |a Gabr, Amrq
|0 P:(DE-2719)9001956
|b 1
|u dzne
700 1 _ |a Kozlov, Stanislav
|0 P:(DE-2719)2812648
|b 2
700 1 _ |a Blum, David
|b 3
700 1 _ |a Halle, Annett
|0 P:(DE-2719)2812038
|b 4
700 1 _ |a Carvalho, Kevin
|b 5
773 _ _ |a 10.3389/fneur.2021.654850
|g Vol. 12, p. 654850
|0 PERI:(DE-600)2564214-5
|p 654850
|t Frontiers in neurology
|v 12
|y 2021
|x 1664-2295
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/157732/files/DZNE-2021-01189.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/157732/files/DZNE-2021-01189.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:157732
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2812560
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9001956
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2812648
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812038
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-18
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT NEUROL : 2021
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-05-11T13:11:28Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-05-11T13:11:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-18
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-05-11T13:11:28Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-01-28
920 1 _ |0 I:(DE-2719)1013034
|k AG Halle
|l Microglia and Neuroinflammation
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1013034
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21